Substance / Medication

Ziprasidone

Overview

Active Ingredient
ziprasidone
RxNorm CUI
115698

Indications

Warnings and Precautions (5.3) [see] Warnings and Precautions (5.3) [see] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consi

Labeler: ROERIGUpdated: 2025-01-13T00:00:00.000ZFull label on DailyMed

Boxed Warning

FDA Black Box Warning

Warnings and Precautions (5.1) [see] Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. GEODON is not approved for the treatment of patients with dementia-related psychosis.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Adverse Drug Events Related to Ziprasidone: A Meta-analysis of Randomized, Placebo-Controlled Trials.
Harrington Catherine A, English Clayton · Pharmacotherapy · 2011
PMID: 21923584Meta-Analysis
Ziprasidone versus other atypical antipsychotics for schizophrenia.
Komossa Katja, Rummel-Kluge Christine, Hunger Heike et al. · Cochrane Database Syst Rev · 2009
PMID: 19821380Meta-AnalysisFull text (PMC)
Efficacy of olanzapine and ziprasidone for the treatment of schizophrenia: a systematic review.
Matza Louis S, Baker Timothy M, Revicki Dennis A · CNS Drugs · 2005
PMID: 15963000Meta-Analysis
Ziprasidone for schizophrenia and severe mental illness.
Bagnall A, Lewis R A, Leitner M L et al. · Cochrane Database Syst Rev · 2000
PMID: 10796670Meta-Analysis
Ziprasidone for schizophrenia and severe mental illness.
Bagnall A, Lewis R A, Leitner M L · Cochrane Database Syst Rev · 2000
PMID: 11034737Meta-Analysis
Effects of Ziprasidone or Haloperidol on Theory of Mind in Patients With Schizophrenia: A 16-week Pilot Trial.
Zhong Jie, Jia Yuan, Zhu Hong et al. · J Psychiatr Pract · 2024
PMID: 38227725RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ziprasidone (substance)
SNOMED CT
409356003
UMLS CUI
C0380393
RxNorm CUI
115698
Labeler
ROERIG

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.